Ainos, Inc.
AIMDAbout the company
Ainos, Inc., a dual-platform company, focusing artificial intelligencebased smelltech technologies and immune therapeutics. It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data. The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women's health sectors.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
1 / 14
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-30 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-30 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-06-30 Latest source filing: 2026-08-03 Score computed: 2026-11-14 | TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-08-03 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 4✗ 24▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / Book Value per Share1.0x✓Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio1.0x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-65.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-65.7%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xValuation ReasonablenessOE Yield=-138.6%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-43.4%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=1.0x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low196% of trailing low ($0.63)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-134.81%; #5530/6340 (top 87.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.3063; #3674/6449 (top 57.0%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0013; #5010/5247 (top 95.5%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-43.36%; #3805/4519 (top 84.2%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-48.32%; #5096/6202 (top 82.2%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-10.0M✗BuffettPositive and growingFCF Positive and Growing$-4.6M✗LynchPositive and growingOperating Cash Flow$-4.6M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-22.11%, ROA=-70.77%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-43.4%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/10 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-64.3%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/15 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-4.6M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-43.36%; #3805/4519 (top 84.2%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)-28033.3%✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 92.9% vs Rev: -87.7%✗LynchInventory growth < Revenue growthEPS Growth Direction$0.01 (2010) -> $-3.46 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency1/15 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-83.0%✗Ackman>= 5%Positive EPS Growth Frequency2/3 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin -207.8% -> 82.9%, operating margin -10815.0% -> -11268.3%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR49.6%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✓ 1✗ 10▾
No clean pass — all 8 investors flag at least one efficiency criterion
Current Ratio0.13✗Graham>= 2.0ROIC (3-5 yr avg)-42.4%✗Buffett> 10%ROIC - WACC-52.4%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY1.10 -> 1.06✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.00x -> 0.01x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities0.13✗Dreman> 1.5Return on Invested Capital-76.1%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-34.3%; FY2024: ROIC=-39.7%; FY2025: ROIC=-59.5%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/5 years above 12% (latest -59.5%)✗SleepROIC > 12% in a majority of years - Profitability6% pass✓ 4✗ 31▾
15 of 16 flag AIMD's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)1/18 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)-28033.3%✗Graham>= 33% growthNet Income Positive (10+ years)1/18 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-85.2%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-11268.3% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-10.0M✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-440.2%✗Lynch> 15%EBIT / Enterprise Value-65.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-65.7%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-70.77%✗PiotroskiROA > 0ROA Change YoY-51.57% -> -70.77% (delta: -19.20%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-22.11%, ROA=-70.77%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY-153.7% -> 82.9%✓PiotroskiImproved YoYPre-Tax Income / Revenue-106277.4%✗Dreman>= 8%Net Income / Shareholders' Equity-440.2%✗Dreman> 12%Margin of SafetyP/B=1.0x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-115.8% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/15 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-101210.2%✗Ackman>= 15%Net Income / Shareholders Equity-440.2%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-10815.0% (2023) -> -11268.3% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin -207.8% -> 82.9%, operating margin -10815.0% -> -11268.3%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-134.81%; #5530/6340 (top 87.2%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+0.05%; #3457/3702 (top 93.4%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-440.15%; #5052/5226 (top 96.7%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1996; #4235/5884 (top 72.0%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/9 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts7% pass✓ 1✗ 14▾
Split decision: 14 FAIL · 1 PASS · 1 NEUTRAL
Overall verdict✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #2363/2370 (Top 99.7%))✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 1✗ 14▾
11 of 12 flag AIMD's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 3.35, IC: -18.8x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity3.35✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.13✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity3.35✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels3.35✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-18.8x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity3.35✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)-3.3496; #3962/4210 (top 94.1%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 90.7% of shares last year, 25.8% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-06-30 2025-07-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.7Mcurrent | -- | -- | $11.8Mest. | $10.5Mest. | $22.2Mest. | $395.2Mest. | $33.0Best. |
| Revenue | $13.6K↓88% | $152↓97% | $161↓100% | $124.2K↑499% | $20.7K↓83% | $122.1K↓97% | $3.5M↑492% | $594.6K |
| Operating Income | -$13.8M↑6% | -$4.4M↓17% | -$2.3M↑28% | -$14.0M↓1% | -$13.8M↓5% | -$13.2M↑6% | -$14.0M↓261% | -$3.9M |
| Net Income | -$14.5M↑8% | -$4.6M↓12% | -$2.5M↑25% | -$14.8M↑1% | -$14.9M↓8% | -$13.8M↑2% | -$14.0M↓260% | -$3.9M |
| EPS (Diluted) | -- | $-0.62↑37% | $-0.41↓95% | $-3.46↓122% | $-1.56↑54% | $-3.36 | -- | $-0.03 |
| Gross Margin | 78.7%↓4% | 65.1%↓18% | -373.9%↓551% | 82.9%↑154% | -153.7%↑26% | -207.8%↓620% | 39.9%↓42% | 69.0% |
| Operating Margin | -101210.2%↓670% | -2894135.5%↓3503% | -1418414.3%↓47529% | -11268.3%↑83% | -66772.2%↓517% | -10815.0%↓2624% | -397.1%↑39% | -650.5% |
| ROE | -440.2%↓220% | — | — | -195.3%↓104% | -95.8%↓70% | -56.3%↓39% | -40.4%↓6% | -38.1% |
| Total Debt | $11.0M | $11.0M | $11.0M↓8% | $11.0M↓8% | $12.0M↑101% | $6.0M↑575% | $884.0K↑314% | $213.4K |
| Shareholders' Equity | $3.3M↓71% | $3.3M↓71% | $5.7M↓57% | $7.6M↓51% | $15.5M↓37% | $24.4M↓29% | $34.6M↑240% | $10.2M |
| Current Ratio | 0.13↓95% | 0.13↓95% | 0.55↓72% | 1.06↓4% | 1.10↓41% | 1.85↑61% | 1.15↑1488% | 0.07 |
| Debt / Equity | 3.35↑248% | 3.35↑248% | 1.93↑111% | 1.45↑88% | 0.77↑217% | 0.24↑856% | 0.03↑22% | 0.02 |
| Operating Cash Flow | -$4.5M↑9% | -$1.4M↓7% | -$983.4K↑20% | -$4.6M↑21% | -$5.8M↓24% | -$4.7M↓54% | -$3.0M↓143% | -$1.2M |
| Free Cash Flow | -- | -$1.5M | -$992.0K↑21% | -$4.6M↑20% | -$5.8M↓22% | -$4.8M↓30% | -$3.7M↓164% | -$1.4M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
AIMD vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |